Biologics and Biosimilars - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Biologics and Biosimilars - Global Top Players Market Share and Ranking 2025

Biologics and Biosimilars - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-13
Report Id: 2765152
Industry: Pharma & Healthcare
Report Page: 114
Chart: 116

PDF Download

Publication Date: 2025-11-13
Report Id: 2765152
Industry: Pharma & Healthcare
Report Page: 114
Chart: 116

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Biologics and Biosimilars Definition
1.2 Global Biologics and Biosimilars Market Size and Forecast
1.3 China Biologics and Biosimilars Market Size and Forecast
1.4 Share of China Biologics and Biosimilars Market with Respect to the Global Market
1.5 Biologics and Biosimilars Market Size: China VS Global Growth Rate, 2020-2031
1.6 Biologics and Biosimilars Market Dynamics
1.6.1 Biologics and Biosimilars Market Drivers
1.6.2 Biologics and Biosimilars Market Restraints
1.6.3 Biologics and Biosimilars Industry Trends
1.6.4 Biologics and Biosimilars Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Biologics and Biosimilars, Global Market Share by Company, 2020-2025
2.2 Global Biologics and Biosimilars Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Biologics and Biosimilars Concentration Ratio
2.4 Global Biologics and Biosimilars Mergers & Acquisitions, Expansion Plans
2.5 Global Biologics and Biosimilars Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Biologics and Biosimilars, China Market Share by Company, 2020-2025
3.2 China Biologics and Biosimilars Biologics and Biosimilars Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Biologics and Biosimilars Industry Chain
4.2 Biologics and Biosimilars Upstream Analysis
4.2.1 Biologics and Biosimilars Core Raw Materials
4.2.2 Main Manufacturers of Biologics and Biosimilars Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Biologics and Biosimilars Production Mode
4.6 Biologics and Biosimilars Procurement Model
4.7 Biologics and Biosimilars Industry Sales Model and Sales Channels
4.7.1 Biologics and Biosimilars Sales Model
4.7.2 Biologics and Biosimilars Typical Distributors

5 Sights by Type
5.1 Biologics and Biosimilars Classification by Type
5.1.1 Monoclonal Antibodies
5.1.2 Interferon
5.1.3 Insulin
5.1.4 Vaccines
5.1.5 Others
5.2 by Type, Global Biologics and Biosimilars Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Biologics and Biosimilars Consumption Value, 2020-2031

6 Sights by Therapeutic Area
6.1 Biologics and Biosimilars Classification by Therapeutic Area
6.1.1 Oncology
6.1.2 Autoimmune Diseases
6.1.3 Endocrinology & Diabetes
6.1.4 Hematology
6.1.5 Other
6.2 by Therapeutic Area, Global Biologics and Biosimilars Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Therapeutic Area, Global Biologics and Biosimilars Consumption Value, 2020-2031

7 Sights by Route of Administration
7.1 Biologics and Biosimilars Classification by Route of Administration
7.1.1 Injectable
7.1.2 Inhalable Formulations
7.1.3 Oral Biologics
7.2 by Route of Administration, Global Biologics and Biosimilars Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Route of Administration, Global Biologics and Biosimilars Consumption Value, 2020-2031

8 Sights by Application
8.1 Biologics and Biosimilars Segment by Application
8.1.1 Hospital
8.1.2 Retail Pharmacy
8.1.3 Other
8.2 by Application, Global Biologics and Biosimilars Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global Biologics and Biosimilars Consumption Value, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global Biologics and Biosimilars Consumption Value, 2020 VS 2024 VS 2031
9.2 By Region, Global Biologics and Biosimilars Consumption Value, 2020-2031
9.3 North America
9.3.1 North America Biologics and Biosimilars Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Biologics and Biosimilars Market Size Market Share
9.4 Europe
9.4.1 Europe Biologics and Biosimilars Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Biologics and Biosimilars Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Biologics and Biosimilars Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Biologics and Biosimilars Market Size Market Share
9.6 South America
9.6.1 South AmericaBiologics and Biosimilars Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Biologics and Biosimilars Market Size Market Share
9.7 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global Biologics and Biosimilars Market Size & CAGR, 2020 VS 2024 VS 2031
10.2 By Country, Global Biologics and Biosimilars Consumption Value, 2020-2031
10.3 United States
10.3.1 United States Biologics and Biosimilars Market Size, 2020-2031
10.3.2 by Type, United States Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.3.3 by Application, United States Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Biologics and Biosimilars Market Size, 2020-2031
10.4.2 by Type, Europe Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.4.3 by Application, Europe Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.5 China
10.5.1 China Biologics and Biosimilars Market Size, 2020-2031
10.5.2 by Type, China Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.5.3 by Application, China Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Biologics and Biosimilars Market Size, 2020-2031
10.6.2 by Type, Japan Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.6.3 by Application, Japan Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Biologics and Biosimilars Market Size, 2020-2031
10.7.2 by Type, South Korea Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.7.3 by Application, South Korea Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Biologics and Biosimilars Market Size, 2020-2031
10.8.2 by Type, Southeast Asia Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.8.3 by Application, Southeast Asia Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.9 India
10.9.1 India Biologics and Biosimilars Market Size, 2020-2031
10.9.2 by Type, India Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.9.3 by Application, India Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Biologics and Biosimilars Market Size, 2020-2031
10.10.2 by Type, Middle East & Africa Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031
10.10.3 by Application, Middle East & Africa Biologics and Biosimilars Consumption Value Market Share, 2024 VS 2031

11 Company Profile
11.1 Roche
11.1.1 Roche Company Information, Head Office, Market Area, and Industry Position
11.1.2 Roche Company Profile and Main Business
11.1.3 Roche Biologics and Biosimilars Models, Specifications, and Application
11.1.4 Roche Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.1.5 Roche Recent Developments
11.2 Amgen
11.2.1 Amgen Company Information, Head Office, Market Area, and Industry Position
11.2.2 Amgen Company Profile and Main Business
11.2.3 Amgen Biologics and Biosimilars Models, Specifications, and Application
11.2.4 Amgen Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.2.5 Amgen Recent Developments
11.3 AbbVie
11.3.1 AbbVie Company Information, Head Office, Market Area, and Industry Position
11.3.2 AbbVie Company Profile and Main Business
11.3.3 AbbVie Biologics and Biosimilars Models, Specifications, and Application
11.3.4 AbbVie Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.3.5 AbbVie Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
11.4.2 Sanofi Company Profile and Main Business
11.4.3 Sanofi Biologics and Biosimilars Models, Specifications, and Application
11.4.4 Sanofi Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.4.5 Sanofi Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
11.5.2 Johnson & Johnson Company Profile and Main Business
11.5.3 Johnson & Johnson Biologics and Biosimilars Models, Specifications, and Application
11.5.4 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.5.5 Johnson & Johnson Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
11.6.2 Pfizer Company Profile and Main Business
11.6.3 Pfizer Biologics and Biosimilars Models, Specifications, and Application
11.6.4 Pfizer Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.6.5 Pfizer Recent Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
11.7.2 Novo Nordisk Company Profile and Main Business
11.7.3 Novo Nordisk Biologics and Biosimilars Models, Specifications, and Application
11.7.4 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.7.5 Novo Nordisk Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
11.8.2 Eli Lilly Company Profile and Main Business
11.8.3 Eli Lilly Biologics and Biosimilars Models, Specifications, and Application
11.8.4 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.8.5 Eli Lilly Recent Developments
11.9 Novartis
11.9.1 Novartis Company Information, Head Office, Market Area, and Industry Position
11.9.2 Novartis Company Profile and Main Business
11.9.3 Novartis Biologics and Biosimilars Models, Specifications, and Application
11.9.4 Novartis Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.9.5 Novartis Recent Developments
11.10 Merck
11.10.1 Merck Company Information, Head Office, Market Area, and Industry Position
11.10.2 Merck Company Profile and Main Business
11.10.3 Merck Biologics and Biosimilars Models, Specifications, and Application
11.10.4 Merck Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.10.5 Merck Recent Developments
11.11 Biogen
11.11.1 Biogen Company Information, Head Office, Market Area, and Industry Position
11.11.2 Biogen Company Profile and Main Business
11.11.3 Biogen Biologics and Biosimilars Models, Specifications, and Application
11.11.4 Biogen Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.11.5 Biogen Recent Developments
11.12 Celltrion
11.12.1 Celltrion Company Information, Head Office, Market Area, and Industry Position
11.12.2 Celltrion Company Profile and Main Business
11.12.3 Celltrion Biologics and Biosimilars Models, Specifications, and Application
11.12.4 Celltrion Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.12.5 Celltrion Recent Developments
11.13 Sobi
11.13.1 Sobi Company Information, Head Office, Market Area, and Industry Position
11.13.2 Sobi Company Profile and Main Business
11.13.3 Sobi Biologics and Biosimilars Models, Specifications, and Application
11.13.4 Sobi Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.13.5 Sobi Recent Developments
11.14 3SBIO
11.14.1 3SBIO Company Information, Head Office, Market Area, and Industry Position
11.14.2 3SBIO Company Profile and Main Business
11.14.3 3SBIO Biologics and Biosimilars Models, Specifications, and Application
11.14.4 3SBIO Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.14.5 3SBIO Recent Developments
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Information, Head Office, Market Area, and Industry Position
11.15.2 Changchun High Tech Company Profile and Main Business
11.15.3 Changchun High Tech Biologics and Biosimilars Models, Specifications, and Application
11.15.4 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.15.5 Changchun High Tech Recent Developments
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Information, Head Office, Market Area, and Industry Position
11.16.2 Kanghong Pharma Company Profile and Main Business
11.16.3 Kanghong Pharma Biologics and Biosimilars Models, Specifications, and Application
11.16.4 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.16.5 Kanghong Pharma Recent Developments
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Information, Head Office, Market Area, and Industry Position
11.17.2 Innovent Biologics Company Profile and Main Business
11.17.3 Innovent Biologics Biologics and Biosimilars Models, Specifications, and Application
11.17.4 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.17.5 Innovent Biologics Recent Developments
11.18 Gan&Lee
11.18.1 Gan&Lee Company Information, Head Office, Market Area, and Industry Position
11.18.2 Gan&Lee Company Profile and Main Business
11.18.3 Gan&Lee Biologics and Biosimilars Models, Specifications, and Application
11.18.4 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.18.5 Gan&Lee Recent Developments
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Information, Head Office, Market Area, and Industry Position
11.19.2 Tonghua Dongbao Company Profile and Main Business
11.19.3 Tonghua Dongbao Biologics and Biosimilars Models, Specifications, and Application
11.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.19.5 Tonghua Dongbao Recent Developments
11.20 United Laboratory
11.20.1 United Laboratory Company Information, Head Office, Market Area, and Industry Position
11.20.2 United Laboratory Company Profile and Main Business
11.20.3 United Laboratory Biologics and Biosimilars Models, Specifications, and Application
11.20.4 United Laboratory Biologics and Biosimilars Revenue and Gross Margin, 2020-2025
11.20.5 United Laboratory Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Biologics and Biosimilars should grow from US$ 469246 million in 2024 to US$ 809409 million by 2031, with a CAGR of 8.1% for the period of 2025-2031.

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products. A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.The average gross profit margin of this product is 76%.

Biologics and Biosimilars

According to YH Research, the global market for Biologics and Biosimilars should grow from US$ 469246 million in 2024 to US$ 809409 million by 2031, with a CAGR of 8.1% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The growth of the biologics and biosimilars market is driven by the rise of precision medicine, increasing prevalence of chronic and rare diseases, and the demand for cost-effective therapies. Advances in genetic engineering, cell culture, protein expression, and delivery systems have accelerated the development of next-generation antibodies and fusion proteins. Meanwhile, the establishment of harmonized biosimilar regulatory pathways worldwide provides new opportunities for emerging companies and markets. Government incentives supporting innovation and generic substitution further fuel market expansion and diversification.

The key challenges in this field include high manufacturing complexity, difficulty in ensuring batch-to-batch consistency, and regulatory heterogeneity across global markets. Biologics development requires significant time and investment, with stringent standards for cold chain logistics and process validation. Although biosimilars offer lower costs, their adoption is still influenced by physician perception, brand loyalty, and reimbursement systems. Frequent intellectual property disputes, extended patent exclusivity, and technological barriers further restrict new entrants and limit market competitiveness. Downstream demand is shifting toward personalized and long-term therapies. Demand for biologics continues to rise in oncology, autoimmune disorders, diabetes, and inflammatory diseases, particularly for targeted and immune-modulating biologics. As healthcare reimbursement systems evolve and coverage expands, biosimilar adoption is rapidly increasing in emerging markets. The proliferation of hospital pharmacies, specialty clinics, and at-home injectable treatments is also driving growth in long-acting and user-friendly formulations.

The upstream supply chain for biologics and biosimilars relies heavily on high-purity cell culture media, serum substitutes, recombinant enzymes, buffers, and advanced filtration consumables. Consistent raw material quality and robust supply chains are vital for production reliability. The adoption of recombinant human serum albumin (rHSA), animal-free culture systems, and high-performance bioreactors has significantly reduced batch variability and enhanced efficiency. Automation and digitalization of upstream processes are emerging as key enablers of competitiveness in the biologics manufacturing ecosystem.

This report studies and analyses global Biologics and Biosimilars status and future trends, to help determine the Biologics and Biosimilars market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Biologics and Biosimilars, and provides market size (US$ million) and Year-over-Year growth, considering 2023 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Biologics and Biosimilars market size, history data 2019-2024, and forecast data 2025 -2030, (US$ million)
(2) Global Biologics and Biosimilars by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Biologics and Biosimilars by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Biologics and Biosimilars key consuming regions, consumption value and demand structure
(5) Biologics and Biosimilars industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Market segment by Type, covers
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others

Market segment by Application, can be divided into
Hospital
Retail Pharmacy
Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Biologics and Biosimilars product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Biologics and Biosimilars market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Biologics and Biosimilars market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Biologics and Biosimilars industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions